Multiple Sclerosis researchXchange – December

December / Previous Editions / Subscribe

Featured: Molecular mechanisms associated with multiple sclerosis progression, severity and phenotype

Peter Kosa et al, Neuroimmunological Diseases Section, National Institute of Allergy and Infectious Diseases

Clinic Notes:

Association between Serum Biomarker Profile and Real-World Evidence of Disability in Multiple Sclerosis

Wen Zhu et al, Department of Neurology, University of Pittsburgh

Comparative effectiveness of natalizumab and fingolimod and injectable therapies in patients with pediatric multiple sclerosis: A registry-based retrospective cohort study

Tim Spelman et al, Burnet Institute, Melbourne, Australia

Lab Notes:

B cell depletion attenuates CD27 signaling of T helper cells in multiple sclerosis

Can Ulutekin et al, Institute of Experimental Immunology, University of Zurich

High-dimensional immune profiling of dimethyl fumarate and ocrelizumab in multiple sclerosis

Yinan Zhang et al, Department of Neurology, The Ohio State University Wexner Medical Center

Banner Life Sciences, a uniquely innovative and entrepreneurial pharmaceutical company, identifies unmet clinical needs for patients and consumers. Committed to advancing human health through scientific innovation, Banner Life Sciences combines a proven history of formulation expertise with proprietary technologies to create specialty pharmaceuticals.

DropCite provides a network for readers, researchers, and authors to annotate and discuss emerging research, in line, anywhere, any time. The researchXchange tracks the most recent scientific preprints about Multiple Sclerosis. DropCite’s editorial team showcases the most significant preprints along with comments from the research community. Follow the conversation and hear what the experts are saying by clicking on the links below. You are free to sign up to become a member of the DropCite community if you want to join the conversation.